|
1
|
Genome-wide association study identifies five susceptibility loci for glioma.
|
Nat Genet
|
2009
|
7.62
|
|
2
|
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
|
J Clin Oncol
|
2009
|
5.06
|
|
3
|
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry.
|
Brain
|
2010
|
3.53
|
|
4
|
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
|
Clin Cancer Res
|
2010
|
3.13
|
|
5
|
Chromosome 7p11.2 (EGFR) variation influences glioma risk.
|
Hum Mol Genet
|
2011
|
1.83
|
|
6
|
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile.
|
Mol Cancer
|
2008
|
1.72
|
|
7
|
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.
|
Neuro Oncol
|
2009
|
1.68
|
|
8
|
BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.
|
Int J Cancer
|
2008
|
1.66
|
|
9
|
Genetic risk profiles identify different molecular etiologies for glioma.
|
Clin Cancer Res
|
2010
|
1.59
|
|
10
|
ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target.
|
Cancer Cell Int
|
2010
|
1.54
|
|
11
|
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
|
Clin Cancer Res
|
2012
|
1.54
|
|
12
|
Dynamic history of low-grade gliomas before and after temozolomide treatment.
|
Ann Neurol
|
2007
|
1.48
|
|
13
|
Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis.
|
Neuro Oncol
|
2010
|
1.38
|
|
14
|
IDH1 and IDH2 mutations in gliomas.
|
N Engl J Med
|
2009
|
1.32
|
|
15
|
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
|
Ann Neurol
|
2006
|
1.32
|
|
16
|
Association between glioma susceptibility loci and tumour pathology defines specific molecular etiologies.
|
Neuro Oncol
|
2012
|
1.32
|
|
17
|
Two types of chromosome 1p losses with opposite significance in gliomas.
|
Ann Neurol
|
2005
|
1.26
|
|
18
|
Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma.
|
J Clin Oncol
|
2008
|
1.21
|
|
19
|
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
|
Clin Cancer Res
|
2009
|
1.18
|
|
20
|
Genomic changes in progression of low-grade gliomas.
|
J Neurooncol
|
2008
|
1.12
|
|
21
|
Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
|
Cancer
|
2006
|
1.10
|
|
22
|
Deciphering the 8q24.21 association for glioma.
|
Hum Mol Genet
|
2013
|
1.08
|
|
23
|
RAD51 haploinsufficiency causes congenital mirror movements in humans.
|
Am J Hum Genet
|
2012
|
1.04
|
|
24
|
FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status.
|
J Neurooncol
|
2007
|
1.04
|
|
25
|
Association of telomerase gene hTERT polymorphism and malignant gliomas.
|
J Neurooncol
|
2007
|
1.01
|
|
26
|
Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas.
|
Ann Neurol
|
2005
|
0.97
|
|
27
|
An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.
|
Mol Cancer
|
2010
|
0.95
|
|
28
|
Expression of TLR9 within human glioblastoma.
|
J Neurooncol
|
2008
|
0.95
|
|
29
|
COLD PCR HRM: a highly sensitive detection method for IDH1 mutations.
|
Hum Mutat
|
2010
|
0.94
|
|
30
|
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.
|
Cancer Res
|
2004
|
0.92
|
|
31
|
Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
|
Brain Res
|
2008
|
0.88
|
|
32
|
Detection of IDH1 mutation in the plasma of patients with glioma.
|
Neurology
|
2012
|
0.87
|
|
33
|
Prevalence, clinico-pathological value, and co-occurrence of PDGFRA abnormalities in diffuse gliomas.
|
Neuro Oncol
|
2012
|
0.85
|
|
34
|
Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas.
|
Neuro Oncol
|
2008
|
0.83
|
|
35
|
TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors.
|
Cancer Genet Cytogenet
|
2007
|
0.83
|
|
36
|
Loss of 14q chromosome in oligodendroglial and astrocytic tumors.
|
J Neurooncol
|
2004
|
0.83
|
|
37
|
No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis.
|
J Neurooncol
|
2009
|
0.82
|
|
38
|
TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.
|
J Neurooncol
|
2014
|
0.82
|
|
39
|
NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas.
|
PLoS One
|
2009
|
0.82
|
|
40
|
Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas.
|
Cancer Genet Cytogenet
|
2007
|
0.82
|
|
41
|
Chromosome 9p and 10q losses predict unfavorable outcome in low-grade gliomas.
|
Neuro Oncol
|
2009
|
0.81
|
|
42
|
No association of MDM2 SNP309 with risk of glioblastoma and prognosis.
|
J Neurooncol
|
2007
|
0.81
|
|
43
|
Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas.
|
J Neurosurg
|
2002
|
0.81
|
|
44
|
Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas.
|
Eur J Cancer
|
2010
|
0.81
|
|
45
|
Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.
|
Neuro Oncol
|
2013
|
0.81
|
|
46
|
The renal v-ATPase a4 subunit is expressed in specific subtypes of human gliomas.
|
Glia
|
2012
|
0.80
|
|
47
|
Parental 19q loss and PEG3 expression in oligodendrogliomas.
|
Cancer Genet Cytogenet
|
2004
|
0.79
|
|
48
|
Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
|
Cancer
|
2014
|
0.79
|
|
49
|
Mutational analysis of Rac2 in gliomas.
|
J Neurooncol
|
2008
|
0.79
|
|
50
|
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.
|
J Neurooncol
|
2014
|
0.78
|
|
51
|
Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
|
Cancer
|
2012
|
0.78
|
|
52
|
NFKBIA deletion in glioblastomas.
|
N Engl J Med
|
2011
|
0.77
|
|
53
|
Preferential loss of paternal 19q, but not 1p, alleles in oligodendrogliomas.
|
Ann Neurol
|
2002
|
0.77
|
|
54
|
Transcranial high intensity focused ultrasound therapy guided by 7 TESLA MRI in a rat brain tumour model: a feasibility study.
|
Int J Hyperthermia
|
2013
|
0.77
|
|
55
|
Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors.
|
J Neurooncol
|
2004
|
0.77
|
|
56
|
TP53 mutations but no CHEK2 *1100DelC variant in familial gliomas.
|
Cancer Genet Cytogenet
|
2009
|
0.76
|
|
57
|
Altered cerebral glucose metabolism in an animal model of diabetes insipidus: a micro-PET study.
|
Brain Res
|
2007
|
0.75
|
|
58
|
Correction: ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target.
|
Cancer Cell Int
|
2011
|
0.75
|
|
59
|
Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors.
|
Expert Rev Mol Diagn
|
2012
|
0.75
|
|
60
|
Prevalence of IDH1/2 Mutations in Different Subtypes of Glioma in the North-East Population of Morocco.
|
Asian Pac J Cancer Prev
|
2016
|
0.75
|